DUBLIN–(BUSINESS WIRE)–The “Fiducial
Markers for Lung and Prostate Cancer in Europe and US, Forecast to 2022”
report has been added to ResearchAndMarkets.com’s
The research service provides an end-user and market perspective for the
use of fiducial markers in the US and Europe and provides a five-year
forecast from 2017 to 2022.
15 to 20 million new cases of cancer are diagnosed every year.
Radiotherapy is the gold standard for treatment and is used on more than
3.5 million people and provided as palliative or adjunct treatment for
an additional 3.5 million people, worldwide. Nearly 50 percent of all
cancer patients are estimated to benefit from radiotherapy for disease
management. Radiotherapy is used in cancers that are localized; it can
provide excellent control with no recurrence in the treated area.
Radiotherapy is also frequently used in combination with surgery or
As radiotherapy is a more cost-effective cancer treatment modality,
expanding the services of radiotherapy is necessary for providing
effective treatment strategies for cancer across care settings. Delivery
of radiotherapy with high accuracy and precision – to reduce injury to
normal tissues – is the need of the hour.
Fiducial markers enable providers to accurately locate tumor lesions and
deliver localized and targeted radiotherapy with higher accuracy.
Implantation of gold fiducial markers is a cost-effective method.
Complications from fiducial marker implantation are not common.
Migration of implanted markers is rare and clinically insignificant.
Fiducial markers are now considered the standard of care in the delivery
of modern prostate RT, and their use is recommended, especially at dose
Fiducials are an excellent surrogate for the prostate position and allow
for accurate treatment delivery and minimize the effect of radiation on
surrounding organs. The main purpose of using fiducial markers is to
increase treatment precision were tracking a tumor is difficult.
Fiducial markers are commonly used in prostate and lung cancer and are
still in the early stages of being used in the treatment of breast,
liver and pancreatic cancer.
Lack of clarity on reimbursement, patient selection, lack of training
and skill set, and adoption of CBCT are the main challenges to
widespread adoption of fiducial markers. On the other hand, easy
implantation, low cost, the potential for use in future diagnostic
purpose, and well-established clinical evidence serve as major driving
The unique value of this study is that it provides insights gathered
from more than 150 end users, including oncologists, interventional
radiologists, radiation oncologists, urologists, and pulmonologists. The
key applications covered in the report include breast cancer, liver
cancer, prostate cancer, lung cancer, and pancreatic cancer. In-depth
analysis is provided for prostate and lung cancer.
Key Topics Covered:
1. Executive Summary – Fiducial Markers Market in the United
States and Europe
- US and European Fiducial Markers Market Summary
- Research Scope and Segmentation
2. Market Overview of Fiducial Markers in the United States and
- US and EU Fiducial Markers Market – Cancer Type Snapshot
- EU and US Fiducial Markers Market – Summary
3. US Fiducial Markers Market
- Infrastructure, Prevalence, and Incidence Statistics
- Procedural Volume Breakdown
- Utilization of Radiotherapy in Cancer Treatment
4. Market Analysis
- Revenue Forecast
- US Fiducial Markers Market Explained
- Market Share Analysis
- Procedure Cost and Reimbursement
5. End-user Trends and Perspective
- Cancer Treatment Procedural Volume by Practice Size
- Budget Allocation and Radiotherapy Procedural Volume
- Annual Budget Allocation and Spending on Fiducial Markers
- Introduction of Fiducial Markers to Professionals
- Services that Professionals Require of Manufacturers
- Patient Indication for Using Fiducials in Prostate and Lung Cancer
- Fiducial Marker Usage in the Treatment of Lung Cancer
- Fiducial Marker Usage in the Treatment of Prostrate Cancer
- Placement of Fiducial Markers
- Ideal Fiducial Marker Cost and Patient Adoption
- Key Factors for not Using Fiducial Markers – Lung Cancer
- Key Factors for not Using Fiducial Markers – Prostate Cancer
- Key Challenges with Existing Fiducial Markers – Lung Cancer
- Key Challenges with Existing Fiducials – Prostate Cancer
- Key Criteria for Ideal Fiducial Marker – Lung Cancer
- Key Criteria for Ideal Fiducial Marker – Prostate Cancer
- Fiducial Marker Type Preferences for Prostate and Lung Cancer
- End-user Perspective – Liquid Markers
- End-user Perspective – CBCT
- Endoscopy Approach and Use of Fiducials in MI Surgery
- Image Guidance in the Treatment of Cancer
- Key Buying Criteria
- Impact of Fiducial Marker Adoption – Applications and Potential Use
For more information about this report visit https://www.researchandmarkets.com/r/8b5qtn
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900